Financial Performance - The company reported a revenue of CNY 11,050,452, a decrease of 23.04% compared to the same period last year[21]. - Net profit attributable to shareholders was CNY 225,731.66, down 7.33% year-on-year[21]. - The company’s net profit for the reporting period was CNY 67,590, a decrease of 21.28% compared to the same period last year[27]. - The company’s basic earnings per share decreased by 12.50% to CNY 0.0007[21]. - The net profit for the first half of 2014 was CNY 675,879.98, a decrease of 21.3% compared to CNY 858,626.54 in the same period of the previous year[111]. - The total profit for the period was CNY 1,622,922.65, down from CNY 2,152,548.84, reflecting a decline of 24.6%[111]. - Operating profit was reported at CNY 1,649,922.65, compared to CNY 2,185,788.26, indicating a decrease of 24.5%[111]. - The total comprehensive income for the period was CNY 675,879.98, down from CNY 858,626.54, a decrease of 21.3%[111]. Cash Flow and Assets - The operating cash flow increased by 17.73% to CNY 4,213,145.93 compared to the previous year[21]. - Cash flow from operating activities increased by 17.73% to ¥4,213,145 compared to ¥3,578,711 in the previous year[30]. - The net increase in cash and cash equivalents was ¥6,495,637.86, representing an increase of 81.51% from the previous year[30]. - Cash and cash equivalents at the end of the period totaled CNY 9,550,078.16, up from CNY 4,460,533.89, marking a growth of 114.5%[118]. - The total current assets at the end of the period amount to 221,674,275.63, slightly up from 219,454,992.39 at the beginning of the period[103]. - Non-current assets total 96,112,130.45, an increase from 66,063,300.05 at the start of the period[104]. - The company's total assets reached 317,786,406.08, up from 285,518,292.44, indicating a growth of 11.2%[105]. - The total liabilities increased to 151,086,544.70 from 119,679,311.04, reflecting a rise of 26.2%[105]. Shareholder and Equity Information - The company reported a total share count of 323,270,000, with 10.14% being restricted shares and 89.86% being unrestricted shares[87]. - The largest shareholder, Beijing Dashi Investment Co., Ltd., holds 9.97% of the shares, totaling 32,220,200 shares, which are pledged and frozen[90]. - Lanzhou Asia-Pacific Industrial Group Co., Ltd. holds 8.49% of the shares, totaling 27,454,395 shares, which are also pledged[90]. - The total owner's equity at the end of the period was CNY 166,699,860, reflecting an increase due to capital contributions of CNY 185,000.00[124]. - The company did not distribute any dividends or allocate any reserves during the reporting period[126]. Corporate Actions and Plans - The company plans to issue 150 million shares to raise CNY 67,500,000 for acquiring 100% equity of Lanzhou Weici Pharmaceutical Co., Ltd.[27]. - The company announced plans for a non-public stock issuance, which led to a temporary suspension of trading[83]. - The company is planning to establish a wholly-owned trading company as part of its expansion strategy[83]. - The company has committed to assist in the recovery of assets and will compensate for any shortfall in the recovery of the aforementioned investment[78]. Legal and Compliance Matters - The company has not reported any significant litigation or arbitration matters during the reporting period[54]. - The company does not face any risks of delisting due to legal violations during the reporting period[81]. - The financial report for the half-year has not been audited[80]. - There are no penalties or rectifications reported during the period[80]. Management and Governance - The company has undergone changes in executive leadership, with several resignations reported[83]. - The company has appointed new executives, including a new CFO and independent directors, in April and May 2014[98]. - The company has been actively engaging with shareholders through annual meetings and collective online briefings[83]. - The company has been involved in various significant announcements, including the transfer of equity stakes in associated companies[82]. Investment and Acquisitions - The company completed the acquisition of Lanzhou Weici Pharmaceutical Co., Ltd. for a transaction price of 4 million yuan, resulting in a loss of 606,439 yuan[57]. - The company reported an investment amount of ¥40,996,243.71 during the reporting period, a decrease of 11,281,225.56% compared to ¥52,277,469.27 in the same period last year[35]. - The company is actively pursuing legal actions to recover investments amounting to ¥30,000,000 related to a long-term equity investment[76][77]. Financial Reporting and Accounting Policies - The financial statements are prepared based on the going concern assumption and comply with the relevant accounting standards and disclosure requirements[136]. - The company uses Renminbi as its functional currency for financial reporting[139]. - The accounting treatment for business combinations under common control involves recognizing assets and liabilities at their book values on the merger date[141]. - The company assesses impairment for significant receivables individually, with a threshold of 5 million CNY for accounts receivable and 1 million CNY for other receivables[161].

Financial Performance - The company's operating revenue for 2013 was ¥22,494,467, a decrease of 53.61% compared to ¥48,489,286 in 2012[21]. - Net profit attributable to shareholders for 2013 was ¥2,626,252.61, an increase of 132.42% from ¥1,129,976.74 in 2012[21]. - Basic earnings per share for 2013 were ¥0.0081, up 131.43% from ¥0.0035 in 2012[21]. - The net profit attributable to the parent company was 2.63 million yuan, an increase of 132.42% year-on-year[26]. - The company reported a net profit of CNY 2,626,252.61 in 2013, with no cash dividends distributed to shareholders[62]. - The company reported a total profit for the current period of ¥2,239,338.13, a recovery from a loss of ¥36,299,958.53 in the previous period[171]. - The net profit for the current period is also ¥2,239,338.13, compared to a net loss of ¥36,299,958.53 last year[171]. - The total comprehensive income for the current period, including net profit and other comprehensive income, is 3,125,828,000[181]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥2,200,086.06, a 409.29% increase from -¥711,336.64 in 2012[21]. - The company's operating cash inflow was 26.64 million yuan, down 40.84% from the previous year, while cash outflow was 24.44 million yuan, a decrease of 46.57%[39]. - Cash and cash equivalents at the end of the period increased to ¥3,049,996.96 from ¥876,778.90, marking a significant improvement[175]. - The company reported cash inflows from operating activities totaling ¥26,637,941.89, down from ¥45,026,573.64 in the previous period, a decrease of approximately 40.7%[174]. - The cash outflows from operating activities were ¥24,437,855.83, compared to ¥45,737,910.28 in the previous period, also a decrease of about 46.5%[174]. Assets and Liabilities - Total assets at the end of 2013 were ¥285,518,292.44, reflecting a 15.31% increase from ¥247,614,829.53 at the end of 2012[21]. - The company's total liabilities increased to CNY 119,679,311.04, up from CNY 84,901,676.33, reflecting a growth of 41%[164]. - The total current liabilities reached CNY 99,679,311.04, an increase of 53.4% from CNY 64,901,676.33[164]. - The company's total assets amounted to CNY 285,518,292.44, compared to CNY 247,614,829.53 at the beginning of the year, indicating a growth of 15.3%[164]. - The company's equity attributable to shareholders was CNY 149,270,265.95, a slight increase from CNY 146,644,013.34[164]. Operational Highlights - The company plans not to distribute cash dividends or issue bonus shares for the year[5]. - The company has identified potential risks in its future development, which are detailed in the board report[13]. - The company has not made any changes to its accounting policies or restated previous years' financial data[21]. - The company did not incur any research and development expenses during the reporting period[36]. - The company has maintained consistent accounting policies and has not reported any significant accounting errors during the reporting period[56]. Governance and Management - The company has established a governance structure with the shareholders' meeting as the highest authority, the board of directors as the decision-making body, and the supervisory board for oversight, ensuring effective operation and internal control[134]. - The company has a stable management team with key personnel having extensive experience in various sectors, including finance and engineering[119]. - The independent directors have been in their roles since April 2013, contributing to corporate governance and oversight[120]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to RMB 4.882 million, with an additional RMB 1.186 million from shareholder units, totaling RMB 6.068 million[126]. - The company has a total of 49 employees, including 7 technical personnel, 22 production personnel, 11 sales personnel, 4 financial personnel, and 5 administrative personnel[131]. Strategic Initiatives and Future Outlook - The company plans to enhance the profitability of its subsidiaries and ensure stable cash flow[54]. - The company aims to transition towards the production and sales of pharmaceutical products, despite lacking experience in this sector[55]. - The company plans to continue expanding its market presence and exploring new product development opportunities[186]. - The company has not disclosed any market expansion or acquisition strategies in the current report[120]. - The company is actively pursuing legal action against Beijing Blue Scenic Home to protect its interests and mitigate negative impacts[92]. Legal and Compliance Issues - The company is involved in ongoing bankruptcy liquidation proceedings for its subsidiary Tianjin Luyuan, with no new developments reported[66]. - The company’s subsidiary Tianjin Luyuan is facing a lawsuit with a claim amount of CNY 13,422,689.10, which may impact its financial position[66]. - The company has faced legal challenges related to a loan guarantee for Tianjin Luyuan Ecological Energy Co., Ltd., impacting its subsidiary's operations[102]. - The company has been involved in litigation regarding the enforcement of a court order related to the equity of a subsidiary, which is currently under seal by the Tianjin Second Intermediate People's Court[103]. - The company has not faced any penalties or corrective actions during the reporting period[95].

Financial Performance - The company's operating revenue for Q1 2014 was CNY 2,966,948, a decrease of 65.31% compared to CNY 8,553,376 in the same period last year[8]. - Net profit attributable to shareholders was CNY 231,391.87, down 75.06% from CNY 927,708.01 year-on-year[8]. - The net cash flow from operating activities increased by 10.03% to CNY 4,516,694.51 from CNY 4,105,083.94 in the previous year[8]. - Total assets at the end of the reporting period were CNY 287,593,761.06, reflecting a 0.73% increase from CNY 285,518,292.44 at the end of the previous year[8]. Investment and Acquisition Plans - The company plans to raise CNY 675 million through a private placement to acquire 100% of Lanzhou Weici Pharmaceutical Co., Ltd. and invest in thrombin and traditional Chinese medicine projects[15]. - The expected acquisition price for Weici Pharmaceutical is approximately CNY 4 million, based on the net asset value determined by an asset appraisal agency[15]. - The investment amount for the thrombin and traditional Chinese medicine project is projected to be CNY 52 million[15]. Cash Flow and Receivables - Cash and cash equivalents increased by 432.99% to CNY 16,279,728.15 due to the receipt of equity transfer prepayments[14]. - The company's pre-receivable accounts rose by 460.92% to CNY 12,232,500.76, attributed to an increase in pre-received housing sales payments[14]. - Accounts payable decreased by 48.11% to CNY 11,977,393.35, primarily due to amounts not yet due for settlement[14]. Asset Management and Legal Actions - The company has recognized an impairment provision of 70 million yuan for long-term equity investments, with an expected recoverable amount of 30 million yuan[18]. - The company holds intangible assets in Tongliao City, Inner Mongolia, with a book value of 12,780,401.68 yuan, and plans to assist in the disposal of these assets[20]. - The company has committed to compensate any shortfall in asset recovery, ensuring full compensation in cash or assets if the recoverable amount is less than the book value[20]. - The company is actively pursuing legal action against Blue View Home for asset recovery, aiming to mitigate negative impacts on its financial position[22]. - The company plans to dispose of land use rights in the Inner Mongolia Tongliao Zhu Ri River Ranch, but has faced challenges due to pricing issues and land degradation[22]. Profit Expectations - The company has not provided a warning regarding significant changes in net profit for the first half of 2014, indicating stable expectations[23].